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Abstract
 
Human B cells that coexpress surrogate and conventional light chains (V-preB
 
 
 
L
 
 
 
) show an
unusual heavy and light chain antibody repertoire that display evidence of receptor editing.
However, it is unclear whether V-preB
 
 
 
L
 
 
 
 B cells have been silenced by receptor editing or
still express autoreactive antibodies. Here we report that 68% of the antibodies expressed by
V-preB
 
 
 
L
 
 
 
 B cells are autoreactive. A majority of these autoantibodies are true antinuclear
antibodies (ANA), and 50% of the ANAs are also reactive with a diverse group of antigens that
include dsDNA, ssDNA, immunoglobulin, insulin, and bacterial lipopolysaccharide. Such anti-
bodies are rarely encountered among conventional B cells. We conclude that V-preB
 
 
 
L
 
 
 
 B
cells are a unique subset of normal circulating human B cells that escape central tolerance
mechanisms and express self-reactive antibodies including potentially harmful ANAs.
Key words: surrogate light chains • B lymphocytes • polyreactive • autoantibody
 
Introduction
 
A majority of the antibodies initially produced during human
B cell development are self-reactive, including antinuclear
antibodies (ANAs) and polyreactive antibodies (1). These
autoantibodies typically display a long Ig heavy (IgH) com-
plementarity determining region (CDR)3 enriched in pos-
itively charged residues, a pattern that is believed to favor
self-reactivity especially against DNA (1–5). Most of the
polyreactive antibodies and ANAs are removed from the
repertoire during B cell development thereby ensuring self-
tolerance (1). Three central mechanisms are responsible for
self-reactive antibody silencing: receptor editing, anergy, and
deletion (for review see reference 6). However, central toler-
ance is imperfect, and some self-reactive B cells are exported
from the bone marrow to the periphery where they can be
deleted (7, 8), remain “ignorant” (9), or anergic (10, 11).
The self-reactive B cells that escape deletion are thought
to benefit the organism by producing antibodies that play a
role in the clearance of apoptotic cells and in the initial
immune response to infections (12, 13). In the mouse,
these “natural” antibodies are produced by two subsets of
peripheral B cells: B1 cells and marginal zone B cells, both
of which are positively selected by self-antigens (14–16).
Natural antibodies are also found in human serum (17),
but the human counterpart of the murine natural antibody
producing B cell is not well defined. CD5, a molecule
specifically expressed on mouse B-1a B cells, is expressed
at variable levels on all human peripheral blood B cells and
therefore cannot be used as a marker for the human counter-
part of murine B1-a B cells (18, 19). Thus, there is little
understanding of the origin of self-reactive antibodies in
humans despite the observation that inappropriate autoanti-
body production is a characteristic of most autoimmune
diseases including rheumatoid arthritis and systemic lupus
erythematosus (20).
We have identified a population of human B cells that
coexpress surrogate and conventional light chains, V-preB
 
 
 
L
 
 
 
B cells, whose antibodies display sequence features that
suggested that they might be self-reactive (5, 21). How-
ever, Ig kappa light chain sequences showed evidence of
receptor editing that may have silenced V-preB
 
 
 
L
 
 
 
 B cells
(5). To determine the specificity of the antibodies expressed
 
The online version of this article includes supplemental material.
Address correspondence to Eric Meffre, The Hospital for Surgery, 535
E. 70th St., New York, NY 10021. Phone: (212) 774-2347; Fax: (212)
717-1192; email: meffree@hss.edu; or Michel C. Nussenzweig, The
Rockefeller University, 1230 York Ave., New York, NY 10021. Phone:
(212) 327-8067; Fax: (212) 327-8370; email: nussen@mail.rockefeller.edu 
Human V-preB
 
 
 
L
 
 
 
 B Cells Express ANAs
 
146
 
by V-preB
 
 
 
L
 
 
 
 B cells, we sorted single B cells from two
unrelated healthy donors, cloned their IgH and Ig light
chains, expressed the recombinant antibodies, and tested
them for self-reactivity. Here we report that the majority of
V-preB
 
 
 
L
 
 
 
 B cells produce self-reactive and polyreactive
antibodies.
 
Materials and Methods
 
Single Cell Sorting.
 
All samples were collected after signed
informed consent in accordance with Institutional Review
Board–reviewed protocols. V-preB
 
 
 
L
 
 
 
B cells and conventional
V-preB
 
 
 
L
 
  
 
B cells were purified from the blood of two nonre-
lated healthy donors using a combination of magnetic bead posi-
tive and negative selection, followed by two rounds of cell sort-
ing (5). Enriched B cells were stained with FITC human anti-
 
 
 
and anti-
 
 
 
, PE human anti–V-preB (a gift from C. Schiff, Centre
d’Immunologie de Marseille-Luminy, Marseille, France), and
APC anti-CD19 (BD Biosciences). V-preB
 
 
 
L
 
 
 
CD19
 
 
 
 B cells and
V-preB
 
–
 
L
 
 
 
 CD19
 
 
 
 B cells were first bulk sorted on a FACS-
Vantage™ (5). Single cells were obtained by a second sort from
the enriched populations directly into 96-well plates containing
4 
 
 
 
l Lysis solution (0.5
 
 
 
 PBS containing 10 mM DTT, 8 U
RNAsin [Promega]), 0.4 U 5
 
 
 
-3
 
 
 
 RNase Inhibitor (Eppendorf),
and immediately frozen on dry ice. All samples were stored at
–70
 
 
 
C.
 
cDNA, RT-PCR, Antibody Production, and Purification.
 
RNA
from single cells was reverse transcribed in the original 96-well
plate in 12.5-
 
 
 
l reactions containing 100 U of Superscript II RT
(GIBCO BRL) for 45 min at 37
 
 
 
C. RT-PCR reactions, primer
sequences, cloning strategy, expression vectors, antibody expres-
sion, and purification were as described (1). Polyreactive human
M55 mAb (a gift from P. Casali, Weill Medical College of Cor-
nell University) was cloned from a CD5
 
 
 
 B cell line as a positive
control antibody (22). Ig sequences were analyzed by Ig BLAST
comparison with GenBank.
 
ELISAs and Indirect Immunofluorescence Assays.
 
Antibody con-
centration, reactivity against specific antigens, and indirect immu-
nofluorescence were as described (1). M55 was used as a positive
control in all polyreactivity ELISAs (22).
 
Online Supplemental Material.
 
Antibody characteristics from
conventional and V-preB
 
 
 
L
 
 
 
 B cells are presented in Tables S1
 
and S2 available at http://www.jem.org/cgi/content/full/
jem.20031550/DC1.
 
Results
 
Cloning Antibodies from Single V-preB
 
 
 
L
 
 
 
 B Cells.
 
T o
examine the specificity of antibodies produced by human
V-preB
 
 
 
L
 
 
 
 B cells, we cloned antibodies from single IgM-
expressing B cells and expressed them as IgG1. The overall
efficiency of cloning both heavy and light chain genes from
individual B cells was 40–60%. Antibodies composed of
heavy chains and V-preB/
 
 
 
–like with or without conven-
tional light chains were not secreted and could not be as-
sayed.
V-preB
 
 
 
L
 
 
 
 B cells represent only 0.5–1% of all circulat-
ing B cells. To obtain pure populations of these cells, we
initially enriched V-preB
 
 
 
L
 
 
 
 B cell using magnetic beads
and then performed two additional rounds of cell sorting
(Fig. 1). We found that the sequence features of Igs cloned
from single V-preB
 
 
 
L
 
 
 
 B cells were similar to those ob-
tained from batch-sorted cells (5, 21). IgHs displayed in-
creased J
 
H
 
6 usage (20.7% in V-preB
 
 
 
L
 
 
 
 versus 0% in
Figure 1. V-preB L  B cell
purification scheme. Dot plots
show V-preB and Ig    ex-
pression on B cells preenriched
for V-preB expression using
magnetic beads (left), and after
the first sort for V-preB L  (top
right) or conventional V-preB L 
B cells (bottom right). These
populations were subsequently
sorted into 96-well plates during
a second round of cell sorting.
Figure 2. Increased frequency of positively charged amino acids in IgH
CDR3s from V-preB L  B cells. Pie charts show segment size propor-
tional to the number of clones from V-preB L  (left) and V-preB L  B
cells (right) displaying 0, 1, 2, 3, and 4 or more positively charged amino
acids per IgH CDR3. The number of sequences analyzed in each group is
indicated in the center. 
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V-preB
 
 
 
L
 
 
 
 B cells was in germline configuration (Table
S2). We conclude that the sequences of the Igs cloned
from single V-preB
 
 
 
L
 
 
 
 B cells were similar to those ob-
tained from batch-sorted cells and were highly unusual
when compared with Ig sequences cloned from conven-
tional B cells (5, 21).
 
V-preB
 
 
 
L
 
 
 
 B Cell Antibodies Are Self-reactive.
 
 To deter-
mine whether the antibodies expressed by V-preB
 
 
 
L
 
 
 
 B
cells were self-reactive, we expressed 28 antibodies ob-
tained from single V-preB
 
 
 
L
 
 
 
 B cells and compared them
with 21 antibodies from conventional V-preB
 
 
 
L
 
 
 
 B cells.
As an initial screen for self-reactivity, we used a commer-
cially available ELISA for antinuclear antibodies (ANA).
This assay detects antibodies that recognize antigens in
HEp-2 cell lysates, and therefore, reactivity is not restricted
to ANAs but includes a broad spectrum of self-antigens.
We found that 68% of V-preB
 
 
 
L
 
 
 
 antibodies (19 out of
Figure 3. V-preB L  B cells express self-
reactive antibodies. (A) Antibodies from
V-preB L  B cells react against HEp-2 cell
lysates. ELISAs for anti-HEp-2 cell reactiv-
ity using recombinant antibodies from 21
V-preB L  (left) and 28 V-preB L  B cells
(right). The percentage of autoreactive clones
for each fraction is indicated. (B) V-preB L 
antibodies express ANAs. Antibodies from
V-preB L  B cells show various patterns of
ANA including nucleolar (KR9), mitotic
spindle apparatus (ED11), speckled (ED20,
ED44), and other uncharacterized patterns
(ED13, ED38, ED41, ED45), and cytoskeletal
reactivity against stress fiber (ED16), vinculin
(ED19), and vimentin (ED37). Antibodies
isolated from conventional B cells such as
EDV-40 do not show ANA staining.
 
V-preB
 
 
 
L
 
 
 
 B cells) and longer CDR3s (15.3 amino acids
in V-preB
 
 
 
L
 
 
 
 versus 12.2 amino acids in V-preB
 
 
 
L
 
 
 
 B
cells, P 
 
  
 
0.005). In addition, we found that antibodies
from V-preB
 
 
 
L
 
 
 
 B cells showed an increased prevalence
of basic amino acid residues in IgH CDR3s (Fig. 2). As in
batch-sorted cells, Ig
 
 
 
 genes from single V-preB
 
 
 
L
 
 
 
 B cells
showed increased downstream J
 
 
 
3, J
 
 4, and J 5 segment
usage compared with Ig s from conventional V-preB L 
B cells (27.5% in V-preB L  versus 16.5% in V-preB L 
B cells) (Tables S1 and S2, available at http://www.
jem.org/cgi/content/full/jem.20031550/DC1) (5). V-preB L 
B cells also displayed increased incidence of V 4–1,
which has been associated with anti-DNA antibodies
(13.6% in V-preB L  versus 0% in V-preB L  B cells)
(23), and an increase in 11–amino acid–long Ig  CDR3s
due to increased N addition (5) (Tables S1 and S2).
Finally, 97% of Ig sequences isolated from singleHuman V-preB L  B Cells Express ANAs 148
28) showed reactivity against HEp-2 cell lysates compared
with 14.5% of antibodies (3 out of 21) isolated from
V-preB L  B cells (Fig. 3 A). Finding that 14.5% of the
antibodies from conventional B cells reacted with HEp-2
cell lysate was consistent with previous reports that 10–30%
of IgMs from peripheral B cells transformed by Epstein-
Barr Virus were similarly reactive and that 20% of naive B
cells expressed such antibodies (1, 24, 25). To determine
whether the HEp-2 ELISA-reactive antibodies were true
ANAs, we performed indirect immunofluorescence assays
(IFAs). Overall, 54% of V-preB L  antibodies tested
showed true ANA reactivity in several distinct staining pat-
terns including nucleolar (KR9), mitotic spindle apparatus
(ED11), speckled (ED20, ED44), and other uncharacter-
ized patterns (ED13, ED38, ED41, ED45) (Fig. 3 B).
Three of the HEp-2–reactive antibodies expressed by
V-preB L  B cells that were not ANAs displayed reactiv-
ity against the cytoskeleton with patterns reminiscent of
anti–stress fiber (ED16), antivinculin (ED19), and antivi-
mentin (ED37) antibodies (Fig. 3 B). In contrast, none of
the 21 antibodies cloned from conventional V-preB L 
B cells showed authentic ANA staining. We conclude that
a high proportion of V-preB L  B cells express ANAs and
other self-reactive antibodies, whereas conventional B cells
rarely express ANAs.
V-preB L  B Cell Antibodies Are Polyreactive. Autoanti-
bodies reactive against DNA and Ig are prevalent in the se-
rum of patients with systemic lupus erythematosus and
rheumatoid arthritis, respectively. To determine whether
V-preB L  antibodies recognize such antigens, we per-
formed ELISAs for single-stranded DNA (ssDNA), double-
stranded DNA (dsDNA), IgM, insulin, and lipopolysaccha-
ride (LPS) (Fig. 4). As a positive control for polyreactivity,
we used M55, a well-characterized polyreactive human an-
tibody (22). 43% of antibodies expressed by V-preB L  cells
(12 out of 28) recognized at least one of the above antigens
and 32% (9 out of 28) bound to two or more antigens and
were therefore polyreactive (Fig. 4). All of the polyreactive
antibodies isolated from V-preB L  B cells showed long
IgH CDR3s enriched in positively charged, hydrophobic,
and aromatic amino acid residues encoded by unusual D
reading frames and germline JH6 segments (Fig. 5). Thus,
the polyreactive antibodies showed the typical signature of
V-preB L  Igs (5, 21). In contrast, only 4.8% (1 out of 21)
of the antibodies expressed by conventional B cells were
polyreactive, and these antibodies showed lower levels of
reactivity than those from V-preB L  or M55 controls (Fig.
4). Similar low frequencies of polyreactivity were found in
93 antibodies cloned from naive human B cells (1). The one
weakly polyreactive antibody isolated from conventional B
cells differed from V-preB L  polyreactive antibodies in
having a short IgH CDR3 without positively charged resi-
dues (KRV-18; Table S1). We conclude that antibodies ex-
pressed by V-preB L  B cells are frequently polyreactive.
Discussion
V-preB L  B cells are a subset of circulating human B
cells that express antibodies with sequence features that
have been associated with self-reactivity (5, 21). However,
Figure 4. V-preB L  antibodies are polyreactive. Recombinant anti-
bodies from conventional V-preB L  (left) and V-preB L  B cells (right)
were tested for anti–single-stranded DNA (ssDNA), double-stranded
DNA (dsDNA), IgM, insulin, and LPS reactivity by ELISA. Human M55
mAb (dotted line) was included as a positive control polyreactive antibody
(22). The percentage of polyreactive clones for each fraction is indicated.Meffre et al. Brief Definitive Report 149
antibody sequences alone cannot predict autoreactivity (1).
Indeed, transgenic mouse B cells that express authentic self-
reactive heavy chains usually produce innocuous antibodies
because of light chain receptor editing (26). To determine
whether V-preB L  B cells express self-reactive antibodies,
we cloned antibodies from purified single cells. We report
herein that most V-preB L  B cells express self-reactive
antibodies. Antibodies produced by V-preB L  B cells dif-
fer from low affinity self-reactive or polyreactive antibodies
produced by 10–20% of all naive peripheral B cells in sev-
eral respects (1, 24, 25). V-preB L  antibodies show higher
affinities for self-antigens, and most V-preB L  antibodies
are true ANAs, whereas these are infrequent ( 4%) among
conventional B cells (1). In addition, V-preB L  antibodies
display specific sequence features that are associated with
autoantibodies (5, 21). They frequently have long CDR3s
enriched in aromatic and positively charged amino acids, a
combination that favors anti-DNA reactivity (2–5). Posi-
tively charged amino acids can interact with the negatively
charged phosphate backbone in nucleic acids, and long
CDR3s enriched in aromatic residues may facilitate the in-
teraction by stacking (27, 28). These features may also favor
polyreactivity by creating a flexible binding site (29).
55% of early immature B cells found in the bone marrow
of normal humans express ANAs and polyreactive antibod-
ies. The ontology of V-preB L  B cells is unknown, but
their surface features differ from early immature B cell pre-
cursors that also frequently produce self-reactive antibodies
(1). For example, V-preB L  B cells do not express imma-
ture B cell markers such as CD38 and CD10 (5). Most im-
portantly, early immature B cells do not express surface B
cell receptor (1). However, the antibodies expressed by
V-preB L  B cells resemble those found in early immature
B cells in that they are polyreactive antibodies with long
IgH CDR3s and increased frequency of positively charged
residues (1). Most of these self-reactive antibodies are re-
moved from the repertoire during the immature B cell
stage in the bone marrow and in the transition between the
immature B cell and naive B cell stage in the periphery (1).
Thus, very few B cells producing highly polyreactive anti-
bodies and ANAs are found in the mature B cell compart-
ment, but they are highly enriched in the V-preB L  B cell
subpopulation. How tolerance is maintained by V-preB L 
B cells is not known, but these cells do not show low B cell
receptor surface levels, and therefore, they do not resemble
anergic B cells (10).
Since expression of surrogate light chains encoded by
 -like and V-preB genes is normally extinguished in imma-
ture B cells, why do V-preB L  B cells retain V-preB pro-
tein expression after completing B cell development? One
clue to a selective advantage for V-preB expression in these
cells may be that a large number of the V-preB antibodies
bind to DNA. In the mouse, DNA binding antibodies that
carry positively charged residues in IgH CDR3 are silenced
or “edited” by light chains that have CDRs with low iso-
electric points (26). Similarly, in transgenic mice that carry
anti-DNA–reactive antibodies, self-reactive B cells are nor-
mally deleted in early B cell development, but coexpression
of an additional Ig light chain with a low isoelectric point
allows continued development, possibly by dilution of au-
toreactive receptors (30). These dual receptor-expressing B
cells then accumulate in the marginal zone B cell compart-
ment. Human V-preB with an isoelectric point of 5.67
may act as an “editor” and substitute conventional editing
by light chain gene replacement by neutralizing positively
charged IgH CDR3s expressed by V-preB L  B cells. In
contrast, mouse V-preB1 and V-preB2 proteins have
CDRs with isoelectric points of 9.37 and would therefore
be unable to edit antibodies with positively charged IgH
CDR3s. We propose that sustained expression of V-preB
proteins is similar to dual receptor expression in autoreac-
tive mouse B cells (30) and may rescue V-preB L  B cells
from central deletion.
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